Log in
Enquire now
‌

US Patent 9757437 Kallikrein inhibitors and anti-thrombolytic agents and uses thereof

Patent 9757437 was granted and assigned to Dyax on September, 2017 by the United States Patent and Trademark Office.

OverviewStructured DataIssuesContributors

Contents

Is a
Patent
Patent

Patent attributes

Patent Applicant
Dyax
Dyax
Current Assignee
Dyax
Dyax
Patent Jurisdiction
United States Patent and Trademark Office
United States Patent and Trademark Office
Patent Number
9757437
Patent Inventor Names
Henry Blair0
Robert Charles Ladner0
Thomas Beck0
Date of Patent
September 12, 2017
Patent Application Number
14271105
Date Filed
May 6, 2014
Patent Citations Received
‌
US Patent 12084515 Compositions and methods for treatment of diabetic macular edema
0
Patent Primary Examiner
‌
Marsha Tsay
Patent abstract

Methods, kits and compositions are described that include a non-naturally occurring kallikrein inhibitor and an anti-thrombolytic agent, e.g., an anti-fibrinolytic agent, for preventing or reducing blood loss and/or ischemia, e.g., ischemia associated with perioperative blood loss and cerebral ischemia, the onset of systemic inflammatory response, and/or reperfusion injury, e.g., reperfusion injury associated with cerebral ischemia or a focal brain ischemia, e.g., in patients subjected to invasive surgical procedures, especially procedures requiring cardiopulmonary bypass.

Timeline

No Timeline data yet.

Further Resources

Title
Author
Link
Type
Date
No Further Resources data yet.

References

Find more entities like US Patent 9757437 Kallikrein inhibitors and anti-thrombolytic agents and uses thereof

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
Open Query Tool
Access by API
Golden Query Tool
Golden logo

Company

  • Home
  • Press & Media
  • Blog
  • Careers
  • WE'RE HIRING

Products

  • Knowledge Graph
  • Query Tool
  • Data Requests
  • Knowledge Storage
  • API
  • Pricing
  • Enterprise
  • ChatGPT Plugin

Legal

  • Terms of Service
  • Enterprise Terms of Service
  • Privacy Policy

Help

  • Help center
  • API Documentation
  • Contact Us